Generic Name: carfilzomib
Drug Class: Targeted Therapy Medications
Approval Status: Approved
Generic Version Available: No
Kyprolis is a proteasome inhibitor approved for relapsed or refractory multiple myeloma, used alone or in combination with other medications.
Kyprolis is a proteasome inhibitor that targets an enzyme that digests and eliminates excess proteins in myeloma cells. Blocking proteasome activity leads to myeloma cell death.
Clinical trials showed that Kyprolis, in combination with other medications, slows progression of multiple myeloma and prolongs survival.
Kyprolis is administered as an intravenous infusion on two consecutive weeks for three weeks, followed by a two-week rest period before starting another cycle.
Common side effects include fatigue, nausea, fever, shortness of breath,
diarrhea, headache, cough, swelling, insomnia and depletion of red blood cells (anemia), white blood cells (neutropenia) and platelets (thrombocytopenia), which can lead to infections and easy bleeding. It can cause birth defects and should not be used during pregnancy.
For More Info: https://www.kyprolis.com
Patient Assistance Program Info: https://www.amgenassist360.com/patient/kyprolis-cost-nurse-ambassador-assistance/
Last Reviewed: September 7, 2020